|
Treatment
|
COC
|
GV
|
GVBD
|
MI
|
MII
|
|---|
| |
(n)
|
(%)
|
(%)
|
(%)
|
(%)
|
|---|
|
SOF
|
75
|
11/78 (14.6)
|
9/75 (12.0)
|
14/75 (18.7)
|
41/75 (54.7)
|
|
SOF + GM-CSF (1 ng/ml)
|
71
|
11/71 (15.5)
|
5/71 (7.0)
|
13/71 (18.3)
|
42/71 (59.2)
|
|
SOF + GM-CSF (10 ng/ml)
|
59
|
8/59 (13.6)
|
4/59 (6.8)
|
15/59 (25.4)
|
32/59 (54.2)
|
|
SOF + GM-CSF (100 ng/ml)
|
89
|
14/89 (15.7)
|
4/89 (4.5)
|
18/89 (20.2)
|
53/89 (59.6)
|
|
TCM
|
95
|
1/95 (1.0)
|
4/95 (4.2)
|
11/95 (11.6)
|
79/95 (83.2*)
|
- GV Germinal Vesicle, GVBD Geminal Vesicle Break-Down, MI metaphase I.
- MII metaphase II. (*) Indicate significant differences between treatments (P < 0.05).
- (There were 3 replicates for this experiment).
